Launxp Biomedical Co (ROCO:6876) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6876 Launxp Biomedical Co Ltd ROCO:6876
9 GF Score
Price NT$13.05
! 4 Warning Signs
View Full Analysis

What is Launxp Biomedical Co Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

ROCO:6876
9GF Score
Launxp Biomedical Co Ltd ROCO:6876
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Launxp Biomedical Co Business Description

Address 10F, No. 51, Section 2, Gongyi Road, Nantun District, Taichung, TWN, 408
Launxp Biomedical Co Ltd is a company that researches, designs and develops Cancer drug rapid screening platform and Early development evaluation and technology licensing of generic drugs for cancer treatment. The company mainly focuses on the screening of development drugs, formulation of development strategies, project management, planning and execution of regulations and clinical trials, etc.
9GF Score

Get the complete analysis for ROCO:6876

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$13.05
Price